Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MET stock price vs RGA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RGA's multiple
Needs RGA P/E.
Implied fair value · at MET's multiple
Needs MET P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
MetLife, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
REINSURANCE GROUP OF AMERICA, INCORPORATED · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AFLAC INC
MET vs AFL
American International Group, Inc.
MET vs AIG
LINCOLN NATIONAL CORP
MET vs LNC
HARTFORD FINANCIAL SERVICES GROUP, INC.
MET vs HIG
BROWN & BROWN, INC.
MET vs BRO
HANOVER INSURANCE GROUP, INC.
MET vs THG
TRAVELERS COMPANIES, INC.
MET vs TRV
ALLSTATE CORP
MET vs ALL
EVEREST GROUP, LTD.
MET vs EG
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MET will re‑rate to RGA-implied P/E multiples (implied price ≈ $54.82), then sell or trim exposure because the model-derived downside is ~27.9% versus the current $76.04; if you instead believe MET's scale and ROIC (34.9%) justify a sustained premium, hold or selectively add, but the P/E premium versus RGA (16.1x vs 11.6x) heightens risk of mean reversion.
MET trades at a significant premium on a P/E basis versus RGA, producing an implied MET price of $54.82 (‑27.9% from the current $76.04). The premium is driven by MET's higher P/E (16.1x) versus RGA (11.6x) even though P/S is equal (0.6x).
Supporting Metrics
